The weight loss drug Mounjaro from Eli Lilly will soon be available on the Dutch market. Follow our newsletter to stay up to date with its release date. In this article, you can find more information about this weight loss medication.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, a prescription medicine approved by the European Medicines Agency (EMA) and the U.S. FDA for treating patients with type 2 diabetes and obesity.
How does Mounjaro work?
This medicine mimics two hormones that are naturally released in your intestines after eating:
- Glucagon-like peptide-1 (GLP-1): This hormone stimulates the pancreas to release more insulin in response to food, which impacts your blood sugar levels. It also reduces appetite and gives a feeling of fullness.
- Glucose-dependent insulinotropic polypeptide (GIP): This hormone also causes your pancreas to release more insulin after eating.
With Mounjaro, the average weight loss is around 22% over 48 weeks.
What is the difference between Ozempic and Mounjaro?
Ozempic is more well-known as a weight loss medication than Mounjaro. Although they are both injectable, there are some differences. Here is what Ozempic and Mounjaro have in common:
- Both are injected weekly into your abdomen, thigh, or upper arm.
- Both mimic the action of the gut hormone GLP-1.
However, there are differences too: while Ozempic mimics only one gut hormone, Mounjaro mimics two: GLP-1 and GIP, as explained above.
For more information about Mounjaro, please call: 0858 200 200.
